Phenotypic profile of DCs
| . | Nonallergics . | Allergics . | ||||
|---|---|---|---|---|---|---|
| GMDCs . | GM/CCL18DCs . | GM/IL-4DCs . | GMDCs . | GM/CCL18DCs . | GM/IL-4DCs . | |
| HLA-DR | 72.7 ± 33 | 121.2 ± 39.8* | 177 ± 42.6§ | 82.3 ± 28 | 77.5 ± 26.6#,** | 189.1 ± 57.3¶ |
| CD80 | 28.7 ± 15 | 68.3 ± 33.8† | 73.8 ± 41.4‖ | 37.5 ± 14.2 | 27.5 ± 11.3#,‡ | 69.8 ± 51.8 |
| CD86 | 18.7 ± 10 | 33.3 ± 13.8† | 48.1 ± 27.1‖ | 14.3 ± 8.9 | 16.8 ± 7.5#,‡ | 33.3 ± 20.4‖ |
| CD11c | 26.2 ± 10.2 | 21.6 ± 9.4 | 23.4 ± 4.9 | 25.2 ± 4.7 | 20.2 ± 4.2 | 27.0 ± 5.1 |
| CD206 | 24.1 ± 4.2 | 15.1 ± 3.3 | 9.7 ± 3.0¶ | 20.6 ± 4.6 | 20.7 ± 7.8 | 15.1 ± 3.0 |
| CD1a | 9.2 ± 5.3 | 6.2 ± 4.9†‡ | 21.2 ± 9.2‖ | 5.8 ± 6 | 3.7 ± 3.1** | 20.0 ± 8.2¶ |
| CD14 | 47.5 ± 22.3 | 34.8 ± 18.3 | 19.7 ± 9.9‖ | 48.5 ± 32 | 42.7 ± 13.3** | 14.0 ± 6.2‖ |
| CD16 | 27.2 ± 5.8 | 26.6 ± 4.8‡ | 9.7 ± 2.9¶ | 14.5 ± 2 | 18.1 ± 4.6‡ | 5.4 ± 3.0¶ |
| CCR7 | 21.6 ± 4.4 | 30.4 ± 7.6†‡ | 20.2 ± 6.2 | 18.5 ± 8.0 | 31.7 ± 10.7 | 20.5 ± 8.7 |
| CD40 | 3.5 ± 0.2 | 3.8 ± 0.6 | 3.7 ± 1.0 | 4.4 ± 1.8 | 4.5 ± 0.8 | 4.9 ± 1.7 |
| ICOS-L | 0.5 ± 0.4 | 1.6 ± 0.5 | 6.4 ± 1.2¶ | 0.5 ± 0.2 | 1.3 ± 0.7 | 4.0 ± 1.3‖ |
| PD-L1 | 1.3 ± 1.2 | 2.6 ± 1 | 5.8 ± 2.0‖ | 1.1 ± 0.7 | 1.4 ± 0.6 | 4.7 ± 1.4‖ |
| PD-L2 | 6.2 ± 1.8 | 7.7 ± 1.8 | 8.4 ± 3.2 | 4.4 ± 1.4 | 5.2 ± 1.8 | 7.8 ± 4.6 |
| . | Nonallergics . | Allergics . | ||||
|---|---|---|---|---|---|---|
| GMDCs . | GM/CCL18DCs . | GM/IL-4DCs . | GMDCs . | GM/CCL18DCs . | GM/IL-4DCs . | |
| HLA-DR | 72.7 ± 33 | 121.2 ± 39.8* | 177 ± 42.6§ | 82.3 ± 28 | 77.5 ± 26.6#,** | 189.1 ± 57.3¶ |
| CD80 | 28.7 ± 15 | 68.3 ± 33.8† | 73.8 ± 41.4‖ | 37.5 ± 14.2 | 27.5 ± 11.3#,‡ | 69.8 ± 51.8 |
| CD86 | 18.7 ± 10 | 33.3 ± 13.8† | 48.1 ± 27.1‖ | 14.3 ± 8.9 | 16.8 ± 7.5#,‡ | 33.3 ± 20.4‖ |
| CD11c | 26.2 ± 10.2 | 21.6 ± 9.4 | 23.4 ± 4.9 | 25.2 ± 4.7 | 20.2 ± 4.2 | 27.0 ± 5.1 |
| CD206 | 24.1 ± 4.2 | 15.1 ± 3.3 | 9.7 ± 3.0¶ | 20.6 ± 4.6 | 20.7 ± 7.8 | 15.1 ± 3.0 |
| CD1a | 9.2 ± 5.3 | 6.2 ± 4.9†‡ | 21.2 ± 9.2‖ | 5.8 ± 6 | 3.7 ± 3.1** | 20.0 ± 8.2¶ |
| CD14 | 47.5 ± 22.3 | 34.8 ± 18.3 | 19.7 ± 9.9‖ | 48.5 ± 32 | 42.7 ± 13.3** | 14.0 ± 6.2‖ |
| CD16 | 27.2 ± 5.8 | 26.6 ± 4.8‡ | 9.7 ± 2.9¶ | 14.5 ± 2 | 18.1 ± 4.6‡ | 5.4 ± 3.0¶ |
| CCR7 | 21.6 ± 4.4 | 30.4 ± 7.6†‡ | 20.2 ± 6.2 | 18.5 ± 8.0 | 31.7 ± 10.7 | 20.5 ± 8.7 |
| CD40 | 3.5 ± 0.2 | 3.8 ± 0.6 | 3.7 ± 1.0 | 4.4 ± 1.8 | 4.5 ± 0.8 | 4.9 ± 1.7 |
| ICOS-L | 0.5 ± 0.4 | 1.6 ± 0.5 | 6.4 ± 1.2¶ | 0.5 ± 0.2 | 1.3 ± 0.7 | 4.0 ± 1.3‖ |
| PD-L1 | 1.3 ± 1.2 | 2.6 ± 1 | 5.8 ± 2.0‖ | 1.1 ± 0.7 | 1.4 ± 0.6 | 4.7 ± 1.4‖ |
| PD-L2 | 6.2 ± 1.8 | 7.7 ± 1.8 | 8.4 ± 3.2 | 4.4 ± 1.4 | 5.2 ± 1.8 | 7.8 ± 4.6 |
DCs differentiated by different protocols were evaluated for their cell-surface markers by flow cytometry. Data are presented as mean fluorescence intensity ± SEM.
P < .01 (GM/CCL18DCs vs GMDCs).
P < .05 (GM/CCL18DCs vs GMDCs).
P < .05 (GM/CCL18DCs vs GM/IL-4DCs).
P < .001 (GM/IL-4DCs vs GMDCs).
P < .05 (GM/IL-4DCs vs GMDCs).
P < .01 (GM/IL-4DCs vs GMDCs).
P < .05 (GM/CCL18DCs from allergics vs nonallergics).
P < .01 (GM/CCL18DCs vs GM/IL-4DCs).